Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies

Background: CTLA-4 was the first immune checkpoint targeted for cancer therapy and the first target validated by the FDA (Food and Drug Administration) after approval of the anti-CTLA-4 antibody, Ipilimumab. However, clinical response rates to anti-CTLA-4 antibodies are lower while the rates of immu...

Full description

Bibliographic Details
Main Authors: Peng Zhang, Xinxin Xiong, Christian Rolfo, Xuexiang Du, Yan Zhang, Han Yang, Alessandro Russo, Martin Devenport, Penghui Zhou, Yang Liu, Pan Zheng
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
anti-ctla-4 antibody
lung cancer
immunotherapy responsiveness
tcga
treg
adcc/adcp
irae
Online Access:https://www.mdpi.com/2072-6694/12/2/284

Similar Items

Similar Items